Published in Int J Endocrinol on March 11, 2014
Effects of long-term androgen replacement therapy on the physical and mental statuses of aging males with late-onset hypogonadism: a multicenter randomized controlled trial in Japan (EARTH Study). Asian J Androl (2015) 1.39
Recommendations on the diagnosis, treatment and monitoring of hypogonadism in men. Aging Male (2015) 0.97
Effects of long-term treatment with testosterone on weight and waist size in 411 hypogonadal men with obesity classes I-III: observational data from two registry studies. Int J Obes (Lond) (2015) 0.94
Testosterone deficiency and cardiovascular mortality. Asian J Androl (2015) 0.90
Insulin Resistance and Inflammation in Hypogonadotropic Hypogonadism and Their Reduction After Testosterone Replacement in Men With Type 2 Diabetes. Diabetes Care (2015) 0.87
Testosterone and metabolic syndrome. Asian J Androl (2015) 0.85
Association of sex hormones with carotid artery distensibility in men and postmenopausal women: multi-ethnic study of atherosclerosis. Hypertension (2015) 0.81
Testosterone and weight loss: the evidence. Curr Opin Endocrinol Diabetes Obes (2014) 0.80
The emancipation of testosterone from niche hormone to multi-system player. Asian J Androl (2015) 0.77
An update on the role of testosterone replacement therapy in the management of hypogonadism. Ther Adv Urol (2015) 0.75
The Relationships between Anabolic Hormones and Body Composition in Middle-Aged and Elderly Men with Prediabetes: A Cross-Sectional Study. J Diabetes Res (2016) 0.75
Exogenous Testosterone, Aging, and Changes in Behavioral Response of Gonadally Intact Male Mice. J Exp Neurosci (2016) 0.75
Testosterone replacement and cardiovascular safety: no straight and narrow! Clin Med Insights Cardiol (2015) 0.75
Remission of type 2 diabetes in a hypogonadal man under long-term testosterone therapy. Endocrinol Diabetes Metab Case Rep (2017) 0.75
MECHANISMS IN ENDOCRINOLOGY: The sexually dimorphic role of androgens in human metabolic disease. Eur J Endocrinol (2017) 0.75
Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care (2004) 75.82
Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med (2001) 56.11
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet (1998) 34.34
Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA (2003) 25.44
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med (2006) 19.09
Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med (2007) 18.45
Inflammation, stress, and diabetes. J Clin Invest (2005) 17.11
Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature (2006) 15.48
Biology of incretins: GLP-1 and GIP. Gastroenterology (2007) 10.45
The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. BMC Public Health (2009) 9.79
Oxidative stress and diabetic complications. Circ Res (2010) 9.37
Weight gain as a risk factor for clinical diabetes mellitus in women. Ann Intern Med (1995) 7.62
Effect of weight loss with lifestyle intervention on risk of diabetes. Diabetes Care (2006) 7.09
Impact of overweight on the risk of developing common chronic diseases during a 10-year period. Arch Intern Med (2001) 7.07
Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med (2010) 6.63
Gender differences in the regulation of blood pressure. Hypertension (2001) 3.78
Metabolic/bariatric surgery Worldwide 2008. Obes Surg (2009) 3.66
Projecting the future diabetes population size and related costs for the U.S. Diabetes Care (2009) 3.34
The economic burden of obesity worldwide: a systematic review of the direct costs of obesity. Obes Rev (2011) 3.22
Effect of BMI on lifetime risk for diabetes in the U.S. Diabetes Care (2007) 3.02
International Day for the Evaluation of Abdominal Obesity (IDEA): a study of waist circumference, cardiovascular disease, and diabetes mellitus in 168,000 primary care patients in 63 countries. Circulation (2007) 3.01
Pulse pressure--a review of mechanisms and clinical relevance. J Am Coll Cardiol (2001) 2.97
The perils of portliness: causes and consequences of visceral adiposity. Diabetes (2000) 2.96
Effect of long-acting testosterone treatment on functional exercise capacity, skeletal muscle performance, insulin resistance, and baroreflex sensitivity in elderly patients with chronic heart failure a double-blind, placebo-controlled, randomized study. J Am Coll Cardiol (2009) 2.96
Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab (2004) 2.93
Waist circumference and all-cause mortality in a large US cohort. Arch Intern Med (2010) 2.88
Treatment of obesity: need to focus on high risk abdominally obese patients. BMJ (2001) 2.86
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. Diabetologia (2006) 2.82
The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. J Clin Endocrinol Metab (2001) 2.61
Effects of weight loss on regional fat distribution and insulin sensitivity in obesity. Diabetes (1999) 2.48
Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol (2006) 2.46
Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm Res (1973) 2.17
Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide. Int J Obes (Lond) (2011) 2.08
Testosterone suppression in men with prostate cancer leads to an increase in arterial stiffness and hyperinsulinaemia. Clin Sci (Lond) (2003) 2.07
Adipose tissue, inflammation and atherosclerosis. J Atheroscler Thromb (2010) 2.07
Overweight and obesity and weight change in middle aged men: impact on cardiovascular disease and diabetes. J Epidemiol Community Health (2005) 1.98
Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr (2011) 1.94
Can diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese patients with type 2 diabetes mellitus. Ann Surg (2013) 1.91
Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care (2011) 1.91
Long-term safety, tolerability, and weight loss associated with metformin in the Diabetes Prevention Program Outcomes Study. Diabetes Care (2012) 1.78
Redefining type 2 diabetes: 'diabesity' or 'obesity dependent diabetes mellitus'? Obes Rev (2000) 1.76
Sex hormones and hypertension. Cardiovasc Res (2002) 1.74
Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract (2013) 1.71
Does inflammation determine metabolic health status in obese and nonobese adults? J Clin Endocrinol Metab (2013) 1.67
IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med (2012) 1.66
Visceral fat accumulation in men is positively associated with insulin, glucose, and C-peptide levels, but negatively with testosterone levels. Metabolism (1990) 1.63
Testosterone: a metabolic hormone in health and disease. J Endocrinol (2013) 1.63
The role of obesity and type 2 diabetes mellitus in the development of male obesity-associated secondary hypogonadism. Clin Endocrinol (Oxf) (2013) 1.54
Testosterone and metabolic syndrome: a meta-analysis study. J Sex Med (2010) 1.54
Relationship of metabolic risk factors and development of cardiovascular disease and diabetes. Obesity (Silver Spring) (2006) 1.52
A critical analysis of the clinical use of incretin-based therapies: The benefits by far outweigh the potential risks. Diabetes Care (2013) 1.51
Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol (2013) 1.47
Effects of 5-year treatment with testosterone undecanoate on lower urinary tract symptoms in obese men with hypogonadism and metabolic syndrome. Urology (2013) 1.46
Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) (2010) 1.46
Angiopoietin-like proteins: emerging targets for treatment of obesity and related metabolic diseases. FEBS J (2010) 1.35
Diet-induced weight loss is associated with an improvement in beta-cell function in older men. J Clin Endocrinol Metab (2004) 1.35
Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male (2003) 1.33
Testosterone: a vascular hormone in health and disease. J Endocrinol (2013) 1.32
Testosterone replacement therapy with long-acting testosterone undecanoate improves sexual function and quality-of-life parameters vs. placebo in a population of men with type 2 diabetes. J Sex Med (2013) 1.09
Effect of the Mediterranean diet with and without weight loss on markers of inflammation in men with metabolic syndrome. Obesity (Silver Spring) (2013) 1.08
Glucagon-like peptide-1 (GLP-1): a trial of treatment in non-insulin-dependent diabetes mellitus. Eur J Clin Invest (1997) 1.05
Aldosterone, C-reactive protein, and plasma B-type natriuretic peptide are associated with the development of metabolic syndrome and longitudinal changes in metabolic syndrome components: findings from the Jackson Heart Study. Diabetes Care (2013) 1.02
Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol (2012) 1.01
Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med (2013) 1.00
Long-term treatment of hypogonadal men with testosterone produces substantial and sustained weight loss. Obesity (Silver Spring) (2013) 1.00
Relationship of abdominal obesity with cardiovascular disease, diabetes and hyperlipidaemia in Spain. Clin Endocrinol (Oxf) (2009) 0.96
The therapeutics of lifestyle management on obesity. Diabetes Obes Metab (2010) 0.95
Diabesity: therapeutic options. Diabetes Obes Metab (2010) 0.95
Androgen therapy in men with testosterone deficiency: can testosterone reduce the risk of cardiovascular disease? Diabetes Metab Res Rev (2012) 0.94
Testosterone and insulin resistance in the metabolic syndrome and T2DM in men. Nat Rev Endocrinol (2013) 0.93
Testosterone therapy in hypogonadal men results in sustained and clinically meaningful weight loss. Clin Obes (2013) 0.92
Emerging therapies in the treatment of 'diabesity': beyond GLP-1. Trends Pharmacol Sci (2010) 0.91
Abdominal adiposity largely explains associations between insulin resistance, hyperglycemia and subclinical atherosclerosis: the NEO study. Atherosclerosis (2013) 0.89
Effects of androgen supplementation therapy on partial androgen deficiency in the aging male: a preliminary study. Aging Male (2002) 0.88
Body mass index and waist circumference as determinants of coronary artery disease in Taiwanese adults with type 2 diabetes mellitus. Int J Obes (Lond) (2006) 0.87
Changes in A1C levels are significantly associated with changes in levels of the cardiovascular risk biomarker hs-CRP: results from the SteP study. Diabetes Care (2013) 0.86
Obesity and the microvasculature: a systematic review and meta-analysis. PLoS One (2013) 0.85
New options for the treatment of obesity and type 2 diabetes mellitus (narrative review). J Diabetes Complications (2013) 0.84
Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease. Int J Cardiol (2009) 0.82
The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Diabetes Obes Metab (2013) 0.80
Testosterone and the heart. Int J Clin Pract (2012) 0.75
Progressive Improvement of T-Scores in Men with Osteoporosis and Subnormal Serum Testosterone Levels upon Treatment with Testosterone over Six Years. Int J Endocrinol (2014) 0.76
Dynamic Patterns of Testosterone Levels within Individuals and Risk of Prostate Cancer among Hypogonadal Men: A Longitudinal Study. J Urol (2017) 0.75